impact of the nocebo effect on discontinuation of statin therapy due to myopathy in patients with cardiovascular disease – a review
Authors:
- Jakub StanekJSJakub Stanek
- Patrycja SornekPSPatrycja Sornek
- Wiktoria IzdebskaWIWiktoria Izdebska
- Agata BorkowskaABAgata Borkowska
- Radosław CiesielskiRCRadosław Ciesielski
- Anna KaźmierczakAKAnna Kaźmierczak
- Anna KiełbAKAnna Kiełb
- Anna MichAMAnna Mich
- Klaudia PerkowskaKPKlaudia Perkowska
- Igor PawlakIPIgor Pawlak
Open Access
- 18 November 2024
- journal article
- review article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 31, 55769
Abstract
Introduction and purpose of review: Statins are widely used drugs in the prevention of cardiovascular diseases, yet many patients experience side effects of statin use, mainly muscle symptoms, such as myopathy, which often lead to discontinuation of treatment. The aim of this literature review is to assess the role of the nocebo effect in reported muscle symptoms and its impact on statin discontinuation in patients with cardiovascular diseases. Methods: The review analysed the results of several studies, including key publications such as the N-of-1 trial by Wood et al.[1] and the work of Collins et al.[2] on the safety and efficacy of statin therapy. The review covered articles published between 2000 and 2023 that examined the impact of the nocebo effect on statin discontinuation[3-10]. Results: The collected data indicate that the nocebo effect plays a significant role in the reported muscle symptoms during statin use. The study by Wood et al.[1] showed no significant differences in reported symptoms between the groups taking statins, placebo, or receiving no treatment, suggesting that a substantial portion of the symptoms results from the nocebo effect. Similar findings were obtained in the study conducted by the StatinWISE group[4], where patients taking statins and placebo reported a comparable frequency of muscle symptoms. An analysis conducted by Collins et al.[2] indicates that the actual incidence of myopathy associated with statin therapy is much lower than commonly reported. Conclusions: The nocebo effect significantly influences the perceived adverse effects of statins, which may lead to the unjustified discontinuation of these drugs by patients with cardiovascular diseases. Further research is needed to better understand the psychological mechanisms affecting statin tolerance and to develop educational and clinical strategies aimed at minimizing the nocebo effect and improving long-term adherence to therapy.Keywords
This publication has 33 references indexed in Scilit:
- Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)Journal of Cachexia, Sarcopenia and Muscle, 2022
- Statin non-adherence and residual cardiovascular risk: There is need for substantial improvementInternational Journal of Cardiology, 2016
- The nocebo effect in the context of statin intoleranceJournal of Clinical Lipidology, 2016
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin IntoleranceJAMA, 2016
- A Century of Cholesterol and Coronaries: From Plaques to Genes to StatinsCell, 2015
- Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trialJournal of Clinical Lipidology, 2014
- Treatment strategies in patients with statin intolerance: The Cleveland Clinic experienceAmerican Heart Journal, 2013
- Nocebo Effects, Patient-Clinician Communication, and Therapeutic OutcomesJAMA, 2012
- Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO StudyCardiovascular Drugs and Therapy, 2005
- Nonspecific Medication Side Effects and the Nocebo PhenomenonJAMA, 2002